Adjusted Revenue

Adjusted Revenue %Chg

Adjusted Gross Profit

Adjusted Gross Profit %Chg

Adjusted Gross Margin

Adjusted Gross Margin %Chg

Adjusted EBIT

Adjusted EBIT %Chg

Adjusted EBIT Margin

Adjusted EBIT Margin %Chg

Adjusted EBITDA

Adjusted EBITDA %Chg

Adjusted EBITDA Margin

Adjusted EBITDA Margin %Chg

Adjusted Net Income

Adjusted Net Income %Chg

Adjusted Net Income Margin

Adjusted Net Income Margin %Chg

Adjusted EPS

Adjusted EPS %Chg

Adjusted Free Cash Flow (FCF)

Adjusted Free Cash Flow (FCF) %Chg

Adjusted Free Cash Flow Margin

Adjusted Free Cash Flow Margin %Chg

Adjusted Capital Expenditures

Adjusted Capital Expenditures %Chg

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Metric	Dec '27 (E)	Dec '26 (E)	Dec '25 (E)	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20
Adjusted Revenue			346,974.3
Adjusted Gross Profit			—
Adjusted Gross Margin			—
Adjusted EBIT			153,814.1
Adjusted EBIT Margin			44.3%
Adjusted EBITDA			170,504.7
Adjusted EBITDA Margin			49.1%
Adjusted Net Income			121,403.4
Adjusted Net Income Margin			35%
Adjusted EPS			23.6
Adjusted Free Cash Flow (FCF)			50,774.4
Adjusted Free Cash Flow Margin			14.6%
Adjusted Capital Expenditures			-62,522.3